Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE.
CLEOCIN PHOSPHATE vs CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. Clindamycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. It exhibits bacteriostatic activity against susceptible bacteria.
Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. Benzoyl peroxide is an oxidizing agent with bactericidal activity against Propionibacterium acnes, and also has keratolytic and comedolytic effects.
600-2700 mg/day IV/IM in 2-4 divided doses. Typical: 600-900 mg IV q8h or 300-600 mg IM q12h.
Apply a thin film to affected areas twice daily (morning and evening).
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in adults with normal renal and hepatic function; may be prolonged to 4-5 hours in patients with severe hepatic impairment (Child-Pugh C). In neonates, half-life ranges from 8-12 hours, decreasing to adult values by 1 month of age.
Terminal elimination half-life of clindamycin after topical application is approximately 2.4 hours. However, due to slow release from skin depot, effective half-life extends to 6–12 hours, supporting twice-daily dosing. Benzoyl peroxide has a very short half-life (<1 minute) on skin due to rapid decomposition; systemic half-life of benzoic acid is ~0.9 hours.
Approximately 10% as active drug and metabolites in urine, 3.6% in feces; major route is hepatic metabolism to inactive metabolites (N-demethylclindamycin and clindamycin sulfoxide) excreted in bile and feces. Renal excretion accounts for about 10% of the dose, with the remainder eliminated via biliary/fecal route.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. After topical application, systemic absorption is minimal (approximately 10% of applied dose). The absorbed clindamycin is primarily excreted via the kidneys (10% unchanged, 3% as metabolites) and biliary/fecal routes (approximately 4%). Benzoyl peroxide is converted to benzoic acid, which is up to 87% excreted in urine as hippuric acid after conjugation with glycine. Overall, for the combination, renal excretion accounts for ~10%, biliary/fecal ~4%, remainder remains unabsorbed or metabolized locally.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic